Dong-A's Stillen showing robust sales in first quarter

Published: 2007-07-04 06:58:00

Updated: 2007-07-04 06:58:00

Dong-A Pharmaceutical' said it anti-ulcerant drug Stillen recorded brisk sales of 14.0 billion won in the first quarter of this year, thanks to superior efficacy and intensive marketing in the domestic market where homegrown new medicines cannot be viable amid deep distrust on their efficacy.

...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK